Legend Biotech Corp (LEGN) reported disappointing financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-0.22, falling short of Wall Street's consensus estimate of $-0.10 by $0.12. Revenue remained flat at $0.3 billion, matching analyst expectations but indicating challenges in growth.
The results highlight ongoing difficulties for the clinical-stage biopharmaceutical company, which focuses on developing novel therapies for oncology and other indications. Based in Somerset, New Jersey, Legend Biotech is known for its lead product candidate, ciltacabtagene autoleucel (cilta-cel), an autologous CAR-T cell therapy targeting the B-cell maturation antigen (BCMA), a protein associated with multiple myeloma.
In light of these results, the company will host an earnings conference call to provide further insights into its operational performance and strategic direction. Investors are encouraged to review the full earnings release and listen to management's commentary for additional context on the quarter's performance and future outlook.
Looking ahead, Legend Biotech is set to report its next earnings on August 9, 2026, with an EPS estimate of $0.05 and projected revenue of $374.7 million.